E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Teleflex has received Biologics License Application (BLA) approval for EZPLAZ Freeze Dried Plasma (FDP) from the USFDA.
imphoenix82
Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is currently approved in more than 40 countries, including the US, Europe and Japan, for the subcutaneous treatment of non-small cell lung cancer.
imphoenix82
The framework builds on WHO’s Greener pharmaceuticals’ regulatory highway call to action, launched in 2024.
imphoenix82
Bioequivalent to Merck’s Bridion injection, Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery.
imphoenix82
Spring Fertility launches its new Personalized IVF Calculator, designed to provide fertility patients with more accurate, personalized information about their chances of a successful IVF outcome.
imphoenix82
ELISIO-HX dialyzer, featuring NIPRO’s proprietary membrane technology, enhances middle molecule removal while remaining fully compatible with routine hemodialysis practice.
imphoenix82
In eastern Africa, WHO now recommends combining the oral medicine miltefosine with paromomycin injections for treating both kala-azar and post-kala-azar dermal leishmaniasis (PKDL) . In South-East Asia, new combination therapies using liposomal amphotericin B, either alone or together with miltefosine, are recommended for PKDL.
imphoenix82
The partnership will evaluate the use of the Ember Cube and related technologies for Alfresa’s Home Care Delivery service, which delivers specialty medicines directly from medical institutions to patients’ homes.
imphoenix82
GSK has announced plans to establish a major new global research and development (R&D) centre in Cambridge, UK, with plans to vacate its existing R&D site in Stevenage, Hertfordshire, by 2029. The new 300,000-square-foot R&D facility on the Cambridge Biomedical Campus, one of Europe’s largest biomedical research hubs, will become home to GSK’s UK R&D […]
imphoenix82
With this approval, AstraZeneca can market Enhertu in India for the neoadjuvant treatment of adults with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, where trastuzumab deruxtecan is followed by a taxane, trastuzumab and pertuzumab (THP).
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
